<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04871269</url>
  </required_header>
  <id_info>
    <org_study_id>DroMemo</org_study_id>
    <nct_id>NCT04871269</nct_id>
  </id_info>
  <brief_title>The Effect of Dronabinol on the Acquisition and Consolidation of Trauma-Associated Memories</brief_title>
  <official_title>The Effect of Dronabinol on the Acquisition and Consolidation of Trauma-Associated Memories</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Charite University, Berlin, Germany</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Charite University, Berlin, Germany</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the current project is to investigate the impact of an activation of the&#xD;
      cannabinoid system with an exogenous cannabinoid dronabinol (delta-9-tetrahydrocannabinol) on&#xD;
      the formation of intrusive memories after analog trauma.&#xD;
&#xD;
      A well-established stress-film paradigm will be used to induce intrusive symptoms in healthy&#xD;
      participants. In a double-blind placebo-controlled study, the impact of exogenous dronabinol&#xD;
      on intrusive symptoms during exposure to a trauma film will be examined. The primary&#xD;
      hypothesis is that exogenous oral dronabinol will decrease the number of intrusive memories&#xD;
      recorded in the four days following experimental trauma compared with placebo controls.&#xD;
&#xD;
      This project will contribute to the current understanding of intrusive memory formation in&#xD;
      PTSD and may guide the development of future pharmacological preventions.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Recent data suggest that the cannabinoid-system is involved in stress regulation and&#xD;
      posttraumatic stress disorder (PTSD) after traumatic events. In own of our own studies, we&#xD;
      found reduced concentrations of the endocannabinoid arachidonylethanolamide (AEA) in BPD&#xD;
      patients compared to healthy women (see Fig 1a). Furthermore, we found a correlation between&#xD;
      hair concentrations of AEA and cortisol (p = .06; Fig 1b).&#xD;
&#xD;
      Low endocannabinoid signaling has been found in PTSD patients and might even present a&#xD;
      precondition to develop PTSD after trauma. In consequence, increased endocannabinoid&#xD;
      signaling during acquisition and consolidation of traumatic events might be a promising&#xD;
      approach to prevent the development of PTSD. The aim of the current project is to investigate&#xD;
      the impact of an activation of the cannabinoid system with an exogenous cannabinoid&#xD;
      dronabinol (delta-9-tetrahydrocannabinol) on the formation of intrusive memories after analog&#xD;
      trauma.&#xD;
&#xD;
      A well-established stress-film paradigm will be used to induce intrusive symptoms in healthy&#xD;
      participants. In a double-blind placebo-controlled study, the impact of exogenous dronabinol&#xD;
      on intrusive symptoms during exposure to a trauma film will be examined. The primary&#xD;
      hypothesis is that exogenous oral dronabinol will decrease the number of intrusive memories&#xD;
      recorded in the four days following experimental trauma compared with placebo controls.&#xD;
&#xD;
      This project will contribute to the current understanding of intrusive memory formation in&#xD;
      PTSD and may guide the development of future pharmacological preventions.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 1, 2021</start_date>
  <completion_date type="Anticipated">August 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change of Intrusive Memories in the following four days after the intervention</measure>
    <time_frame>four consecutive days</time_frame>
    <description>Influence of dronabinol on the development of intrusive memories measured with an intrusion diary</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Noradrenergic System (measured with salivary alpha-amylase - u/ml)</measure>
    <time_frame>Day 1</time_frame>
    <description>Influence of dronabinol on the noradrenergic system measured with salivary alpha-amylase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hypothalamic-pituitary-adrenal (HPA) axis (measured with salivary cortisol - nmol/L)</measure>
    <time_frame>Time Frame: Day 1</time_frame>
    <description>Influence of dronabinol on the HPA-axis measured with salivary cortisol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Polygenic Risk Score Influence of polygenic risk score on development of intrusive memories</measure>
    <time_frame>Day 1</time_frame>
    <description>Influence of polygenic risk score on development of intrusive memories</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">291</enrollment>
  <condition>Intrusive Memories</condition>
  <arm_group>
    <arm_group_label>Drug: Dronabinol before the trauma film paradigm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Drug: Dronabinol after the trauma film paradigm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo before and after the trauma film paradigm</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dronabinol</intervention_name>
    <description>Dronabinol</description>
    <arm_group_label>Drug: Dronabinol after the trauma film paradigm</arm_group_label>
    <arm_group_label>Drug: Dronabinol before the trauma film paradigm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Drug: Dronabinol after the trauma film paradigm</arm_group_label>
    <arm_group_label>Drug: Dronabinol before the trauma film paradigm</arm_group_label>
    <arm_group_label>Placebo before and after the trauma film paradigm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  healthy female volunteers&#xD;
&#xD;
          -  German on a native level&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  former or present disorder according to the Diagnostic and Statistical Manual of&#xD;
             Mental Disorders 5 (DSM-5)&#xD;
&#xD;
          -  any physical illnesses&#xD;
&#xD;
          -  any medication intake (except oral contraceptive)&#xD;
&#xD;
          -  history of traumatic experience, e.g. history of sexual abuse or rape&#xD;
&#xD;
          -  pregnancy or lactation period&#xD;
&#xD;
          -  follicular phase of menstrual cycle for all women not using oral contraceptives&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stefan Röpke, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Charite University, Berlin, Germany</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Katja Wingenfeld, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Charite University, Berlin, Germany</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tolou Maslahati, M.Sc.</last_name>
    <phone>0049 030 450 517 567</phone>
    <email>tolou.maslahati@charite.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Charité - Universitätsmedizin Berlin</name>
      <address>
        <city>Berlin-Steglitz</city>
        <state>Berlin</state>
        <zip>10249</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tolou Maslahati</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 3, 2021</study_first_submitted>
  <study_first_submitted_qc>May 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 4, 2021</study_first_posted>
  <last_update_submitted>May 3, 2021</last_update_submitted>
  <last_update_submitted_qc>May 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Charite University, Berlin, Germany</investigator_affiliation>
    <investigator_full_name>Stefan Roepke</investigator_full_name>
    <investigator_title>Prof. Dr.</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dronabinol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

